Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

Strong financial position supports clinical focus on advancing drug

candidates for treatment of lysosomal storage disorders

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the first quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.34 per share ($0.28 per share on a non-GAAP basis) for the three months ended March 31, 2008. As of March 31, 2008, cash, cash equivalents, and marketable securities totaled $154.6 million.

"In the first quarter of 2008, we continued to advance our three lead clinical development programs. We also reported data from multiple clinical trials that add to the growing body of evidence demonstrating that treatment with our oral pharmacological chaperone drug candidates has the potential to benefit patients with Fabry, Gaucher and Pompe disease," said John F. Crowley, President and CEO of Amicus Therapeutics. "In the months ahead in 2008, we will be focused on advancing the global regulatory plan for Amigal Phase 3 development, evaluating opportunities for additional clinical studies in Gaucher and Pompe disease, as well as on identifying new therapeutic areas for applying our pharmacological chaperone technology platform."

Program Advancements

Fabry Disease:

Amigal(TM) (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. In March, clinical investiga
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 /PRNewswire-iReach/ -- Think Drinks are a neuroscience-backed ... long term. They are the first functional focus beverage ... as an alternative to the temporary fix associated with ... on July 29, 2014, with hopes to raise $50,000 ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 Think ...
(Date:7/23/2014)... , July 23, 2014  AuraSense Therapeutics, ... as gene regulatory and immunotherapeutic agents, announced ... joined AuraSense Therapeutics, executive leadership team as ... Prior to joining AuraSense Therapeutics, Mr. ... Financial Officer of Cellular Dynamics International Inc., ...
(Date:7/23/2014)... 2014 Shimadzu Scientific Instruments has ... analysis system developed jointly with Ajinomoto Co. Inc. ... analyze 38 amino acids in nine minutes, drastically ... high-speed analysis utilizing a fast application-specific column and ... analytical results even under conditions with difficult samples ...
(Date:7/23/2014)... Last year, Formedix celebrated its partnership ... of data management solutions for clinical trials. The company ... electronic data capture (EDC) and clinical data management. Formedix, ... tools added TrialMaster to its Transform for EDC product ... for TrialMaster, is being released this week, in response ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3
... Among Companies Doing Well, Relationships Weaken in Many CountriesNEW YORK, ... in four out of the five major European countries -- ... marks for effectively delivering key sales and service activities. ... with Novartis in the UK and Germany. In 2008, ...
... FUNDING, ACQUISITION AND INFORMATION MANAGEMENT INITIATIVES TO ACCELERATE GROWTHSHANGHAI, China, ... ("Sinobiomed," or "the Company") (OTC Bulletin Board: SOBM) is pleased ... to accelerate the Company,s growth. The new management team members ... Dr. Anchie Kuo , ...
... Expands its Presence in the Biotech IndustryFT. ... Corporation ("Newbridge"), a full-service securities broker-dealer and ... formation of the Newbridge BioVentures Division ("NBV"). ... services for the biotech industry and related ...
Cached Biology Technology:Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 2Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 3Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 4Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 5Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 6Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US 7Sinobiomed Announces New Executive Team 2Sinobiomed Announces New Executive Team 3Newbridge Securities Corporation Forms BioVentures Division 2
(Date:7/23/2014)... such as tapeworms, hookworms and a protist called Blastocystis ... new paper that argues we should rethink our views of ... the point, paper co-author Julius Luke even ingested three developmental ... latum . After more than a year with the tapeworms, ... metres each by now, he says he feels fine. , ...
(Date:7/23/2014)... Basement membrane degradation and blood-brain barrier damage ... and brain functioning. Matrix metalloproteinase-9 is able ... basement membrane around cerebral blood vessels and ... Huilian Hou and colleagues from the First ... Jiaotong University, China induced cerebral infarction in ...
(Date:7/23/2014)... crucial for providing essential fatty acids and energy ... There has been concern that soybean-based emulsions could ... to its composition. Combination lipid emulsions based on ... been developed to address this concern. , However, ... concern may be unwarranted, according to a review ...
Breaking Biology News(10 mins):Intestinal parasites are 'old friends,' researchers argue 2Intestinal parasites are 'old friends,' researchers argue 3
... CHICAGO (October 24, 2007) New research published in ... College of Surgeons suggests that pregnant women suspected of ... (removal of the appendix) that can result in early ... points to the need to require more accurate diagnosis ...
... The vast majority of patients who had ... did not need mitral valve surgery three years ... improved function of the left ventricle (commonly known ... week at the Cardiovascular Research Foundations (CRF) nineteenth ...
... shepherds and travellers encountering lions, for example the Old ... and people by these fierce predators. Lions have now ... livestock owners around the Waza National Park, Cameroon, living ... human life is rarely reported, lion predation can cost ...
Cached Biology News:Pregnant women at risk for unnecessary operations due to misdiagnosis of appendicitis 2New data shows benefits of MitraClip for patients with mitral regurgitation 2New data shows benefits of MitraClip for patients with mitral regurgitation 3Living with lions 2
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
... to ARG. Vasopressin The antibody ... Cells are found in the paraventricular ... found throughout the hypothalmus in rat ... Immunogen: Arginine ...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Biology Products: